Skip to main content

CAdVEC

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

  • RegistryNCT03740256
  • PhasePhase 1
  • StatusRecruiting
  • ConditionBladder Cancer
  • SponsorBaylor College of Medicine
How VISTA worksNCT037402561 min

What the film says

Read the transcript

Many solid tumors, in breast, stomach, bladder, head and neck, carry a growth receptor called HER2. Anti-HER2 drugs help, but advanced disease outruns them, and CAR T cells alone rarely get a foothold in solid tumors.

The idea: light a fire inside the tumor first, then send in the cells.

At Baylor St. Luke's in Houston, a virus engineered to infect cancer cells, CAdVEC, is injected directly into one reachable tumor. As it replicates, it inflames the site and recruits immune cells. Three days later, the patient's own T cells, given a receptor for HER2, are infused and drawn toward that inflamed tumor and beyond.

VISTA is a first study in people, across HER2-positive cancers. Shalini Makawita leads it. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT03740256

    HER2+ cancers listed (bladder, head and neck, salivary, lung, breast, gastric, esophageal, colorectal, pancreatic); CAR T alone rarely gain a foothold in solid tumors; Intratumoral CAdVEC at one accessible site, day 1; ultrasound / endoscopic guidance; Pro-inflammatory microenvironment; recruits/expands T cells (+2 more lines)

The drug

What is being tested.

The intratumoral administration of CAdVEC will create a pro-inflammatory tumor microenvironment and will promote the recruitment and expansion of adoptively transferred HER2 specific CAR T cells via CAR (tumor antigen). We expect HER2 CAR T cells expanded at primary tumor sites will re-circulate and target metastasized tumors. The combination we propose to test has the potential to overcome each of the established individual limitations of oncolytic viruses and of CAR T-cells.

Treatment with CAdVEC: On the first day of treatment, participants will receive an injection of CAdVEC into their tumor. A blood sample will be obtained from the participant before the CAdVEC intratumor injection . Depending on the location of the tumor, different techniques can be used for the injection into your tumor.

The most common route of injection is ultrasound-guided percutaneous (needle puncture in the skin) injection, but endoscopic (using a lighted, flexible instrument called an endoscope) ultrasound-guidance will be used for some patients as appropriate. Prior to percutaneous injection, participants may receive an anti-anxiety medicine to calm them down, to relieve muscle spasms, and provide sedation.

The study

How the trial runs.

This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer.

This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cells called HER2 chimeric antigen receptor specific cytotoxic T lymphocytes (HER2 specific CAR T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system including HER2 specific CAR T cell react to the tumor.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • This study will look at solid tumors (as a basket trial for any solid cancer) with HER2 positivity based on IHC
  • Procurement Inclusion Criteria
  • The patient has a histologically confirmed advanced refractory HER2 positive solid tumor, including but not limited to: head and neck squamous cell carcinoma; cancer of the salivary glands; lung cancer; breast cancer; bladder cancer; gastric cancer; esophageal cancer; colorectal cancer; and pancreatic adenocarcinoma. HER2 positivity is defined as ≥2+ staining by IHC with either the FDA-approved CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA), which refers to greater than weak-to-moderate staining intensity in >10% tumor cells.
  • The disease must be deemed unsuitable for curative treatments including surgery, radiotherapy, systemic therapy, including checkpoint inhibitors, or any combination of the above modalities by the referring oncology physician and confirmed by the senior oncologists leading the protocol.
  • Disease must have progressed after standard first line therapy, or without available effective treatment options. Patients are still eligible if they have failed more than one line of therapy.
  • The patient must have at least one tumor site appropriate for intratumoral injection.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.